Vials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
The Global Vials Market reached USD 12.2 billion in 2023 and is projected to expand at a CAGR of 9.1% from 2024 to 2032. Vials are small, sealed containers made from glass or plastic, primarily used for storing liquids, powders, or freeze-dried medications. These containers play a crucial role in maintaining the sterility and stability of drugs, particularly in healthcare environments. Vials are commonly used to package vaccines, injectables, and biologics, and they come in both single-use and multi-dose formats. They are sealed with rubber stoppers or caps to prevent contamination before the medication is administered.
The market's growth is largely driven by the increasing demand for pharmaceuticals, particularly injectable drugs and biologics, which require high-quality vials to maintain drug stability and safety. The rise in chronic diseases and the growing emphasis on global vaccination campaigns have significantly boosted the use of vials for storing and distributing vaccines. Additionally, ongoing technological developments in vial models, such as improved glass formulations and tamper-proof type, enhance their appeal and contribute to market growth.
The market is categorized based on preparation into ready-to-use (RTU) and ready-to-sterilize (RTS) vials. The RTU segment currently dominates the market and is expected to grow at a CAGR of 9.4% during the forecast period. RTU vials come with pre-measured doses of medication, reducing the need for further preparation and minimizing the risk of contamination. This feature is particularly beneficial in clinical settings, where efficiency and precision are critical. RTU vials streamline pharmaceutical manufacturing processes by eliminating the need for sterilization and filling, thus reducing labor and operational costs while optimizing production efficiency.
In terms of application, the market is divided into small molecules, biologics, and diagnostics. The biologics segment held the largest share of 48.6% in 2023, driven by the increasing use of biologic therapies to treat chronic conditions, such as autoimmune diseases. As biologics are derived from living organisms, they require specialized packaging to preserve their stability and efficacy, making vials an essential component of their distribution. This segment's growth is further supported by the increasing availability of biosimilars, providing more treatment options for patients.
The U.S. dominates the North American vials market and is expected to continue leading the market with a projected CAGR of 8.8% in 2023. This dominance can be attributed to the country's strong pharmaceutical and biotechnology sectors, which create a high demand for advanced packaging solutions. Significant investments in drug development, particularly in biologics and personalized medicine, emphasize the need for specialized vials that meet stringent regulatory standards while ensuring drug stability and safety.
The market's growth is largely driven by the increasing demand for pharmaceuticals, particularly injectable drugs and biologics, which require high-quality vials to maintain drug stability and safety. The rise in chronic diseases and the growing emphasis on global vaccination campaigns have significantly boosted the use of vials for storing and distributing vaccines. Additionally, ongoing technological developments in vial models, such as improved glass formulations and tamper-proof type, enhance their appeal and contribute to market growth.
The market is categorized based on preparation into ready-to-use (RTU) and ready-to-sterilize (RTS) vials. The RTU segment currently dominates the market and is expected to grow at a CAGR of 9.4% during the forecast period. RTU vials come with pre-measured doses of medication, reducing the need for further preparation and minimizing the risk of contamination. This feature is particularly beneficial in clinical settings, where efficiency and precision are critical. RTU vials streamline pharmaceutical manufacturing processes by eliminating the need for sterilization and filling, thus reducing labor and operational costs while optimizing production efficiency.
In terms of application, the market is divided into small molecules, biologics, and diagnostics. The biologics segment held the largest share of 48.6% in 2023, driven by the increasing use of biologic therapies to treat chronic conditions, such as autoimmune diseases. As biologics are derived from living organisms, they require specialized packaging to preserve their stability and efficacy, making vials an essential component of their distribution. This segment's growth is further supported by the increasing availability of biosimilars, providing more treatment options for patients.
The U.S. dominates the North American vials market and is expected to continue leading the market with a projected CAGR of 8.8% in 2023. This dominance can be attributed to the country's strong pharmaceutical and biotechnology sectors, which create a high demand for advanced packaging solutions. Significant investments in drug development, particularly in biologics and personalized medicine, emphasize the need for specialized vials that meet stringent regulatory standards while ensuring drug stability and safety.
Report Content
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising chronic diseases and geriatric population
3.2.1.2 Rise in biologics and biosimilars
3.2.1.3 Advancements in glass technology
3.2.1.4 Increased trend of outsourcing manufacturing to CDMOs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Access to alternative drug delivery methods
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PREPARATION, 2021 – 2032 ($ MN AND UNITS)
5.1 Key trends
5.2 Ready To Use (RTU)
5.3 Ready To Sterilize (RTS)
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN AND UNITS)
6.1 Key trends
6.2 Small molecules
6.3 Biologics
6.4 Diagnostics
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MATERIAL, 2021 – 2032 ($ MN AND UNITS)
7.1 Key trends
7.2 Glass
7.3 Polymer
7.4 Hybrid
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY SIZE, 2021 – 2032 ($ MN AND UNITS)
8.1 Key trends
8.2 <1 ml
8.3 1 ml - 2 ml
8.4 3 ml - 5 ml
8.5 6 ml - 10 ml
8.6 10 - 20 ml
8.7 20 - 30 ml
8.8 >30 ml
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN AND UNITS)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Pharma & biotech companies
9.4 Contract Development And Manufacturing Organizations (CDMOs)
9.5 Diagnostic laboratories
9.6 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN AND UNITS)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Amcor
11.2 Arab Pharmaceutical Glass
11.3 Corning
11.4 Daikyo Seiko
11.5 DWK Life Sciences
11.6 Gerresheimer AG
11.7 KISHORE GROUP
11.8 Mitsubishi Gas Chemical Company
11.9 Nipro
11.10 Pacific Vial Manufacturing
11.11 SCHOTT Pharma (SCHOTT Group)
11.12 SGD Pharma
11.13 Shandong Province Medicinal Glass
11.14 SHIOTANI GLASS
11.15 Stevanato Group
11.16 West Pharmaceutical Services
11.17 Wuxi NEST Biotechnology
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising chronic diseases and geriatric population
3.2.1.2 Rise in biologics and biosimilars
3.2.1.3 Advancements in glass technology
3.2.1.4 Increased trend of outsourcing manufacturing to CDMOs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Access to alternative drug delivery methods
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PREPARATION, 2021 – 2032 ($ MN AND UNITS)
5.1 Key trends
5.2 Ready To Use (RTU)
5.3 Ready To Sterilize (RTS)
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN AND UNITS)
6.1 Key trends
6.2 Small molecules
6.3 Biologics
6.4 Diagnostics
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MATERIAL, 2021 – 2032 ($ MN AND UNITS)
7.1 Key trends
7.2 Glass
7.3 Polymer
7.4 Hybrid
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY SIZE, 2021 – 2032 ($ MN AND UNITS)
8.1 Key trends
8.2 <1 ml
8.3 1 ml - 2 ml
8.4 3 ml - 5 ml
8.5 6 ml - 10 ml
8.6 10 - 20 ml
8.7 20 - 30 ml
8.8 >30 ml
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN AND UNITS)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Pharma & biotech companies
9.4 Contract Development And Manufacturing Organizations (CDMOs)
9.5 Diagnostic laboratories
9.6 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN AND UNITS)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Amcor
11.2 Arab Pharmaceutical Glass
11.3 Corning
11.4 Daikyo Seiko
11.5 DWK Life Sciences
11.6 Gerresheimer AG
11.7 KISHORE GROUP
11.8 Mitsubishi Gas Chemical Company
11.9 Nipro
11.10 Pacific Vial Manufacturing
11.11 SCHOTT Pharma (SCHOTT Group)
11.12 SGD Pharma
11.13 Shandong Province Medicinal Glass
11.14 SHIOTANI GLASS
11.15 Stevanato Group
11.16 West Pharmaceutical Services
11.17 Wuxi NEST Biotechnology
